Sun Pharma launches Drizalma Sprinkle
Sun Pharma is introducing Drizalma Sprinkle (duloxetine delayed-release capsules) for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a problem that is estimated to affect approximately 30% to 35% of long-term care residents.
The availability of Drizalma Sprinkle expands Sun Pharma’s portfolio of alternative formulation products designed for individuals with swallowing difficulties, the risk of which increases with age and exposure to age-related diseases and conditions - including depression, anxiety, and pain disorders.
Drizalma Sprinkle joins Ezallor Sprinkle (rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate) extended-release capsules as the third product in Sun Pharma’sportfolio designed for individuals in long-term care.
“The launch of Drizalma Sprinkle is an important milestone for people with difficulty swallowing, as this formulation of duloxetine can facilitate treatment of common neuro-psychiatric disorders while preserving the quality of the medicine,” Sun Pharma North America CEO Abhay Gandhi said. ”This launch further underscores our commitment to providing a portfolio of alternative formulation products to treat common diseases – especially in long-term care, where 30-35% of individuals have difficulty swallowing. These patients often encounter medication errors and challenges with medication administration.”
Drizalma Sprinkle is indicated for the treatment of major depressive disorder in adults, generalized anxiety disorder in adults and pediatric patients 7 to 17 years old, diabetic peripheral neuropathic pain in adults, and chronic musculoskeletal pain in adults. It is available in dosage strengths of 20 mg, 30 mg, 40 mg, and 60 mg.
Drizalma Sprinkle is the first and only FDA approved formulation of duloxetine that can be swallowed whole, sprinkled on applesauce or administered via nasogastric tube.